A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of WJ13404 Monotherapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Latest Information Update: 23 Dec 2022
Price :
$35 *
At a glance
- Drugs WJ 004 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Suzhou Junjing BioSciences
- 23 Dec 2022 New trial record